Not checkedNot checked for notices yet.
Modern possibilities of colonoprotection in patients with irritable bowel syndrome
D.T. Janelidze
Gastroenterologìa · 2020
doi:10.22141/2308-2097.54.3.2020.211737 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The literature search was carried out using the Scopus and MedLine databases. Functional bowel disorders are now viewed as a spectrum of intestinal symptoms that form 6 variants: irritable bowel syndrome, functional constipation, functional diarrhea, functional bloating/distension, non-specific functional bowel disorder and opioid-induced constipation. The etiology of irritable bowel syndrome symptoms has not been fully established. The lack of a clear understanding of the pathogenesis of one or another functional intestinal disease, including irritable bowel syndrome, taking into account the presence of various structural and morphological disorders in the intestinal wall, dictates the need to search for new drugs, the action of which will be directed to different links of the pathogenesis of intestinal diseases. The composition of the new original coloprotector Colonzak includes the following ingredients: calcium butyrate — equivalent to 250 mg of butyric acid, fructooligosaccharides (inulin) — 100 mg and a 2.7 billion strains of bifidobacteria (B.bifidum & B.lactis). Taking into account the effects of inulin, butyric acid and bifidobacteria, Colonzak is a coloprotector that restores the energy potential of colonocytes, normalizes mucus formation and goblet cell function, reduces the permeability of the mucous membrane, has a cancer prevention effect on normal colonocytes and inhibits the growth and replication of intestinal tumor cells. Also, being a pre- and probiotic, it creates conditions for the growth and normalization of intestinal microflora, changes in which in varying degrees of severity are found in both inflammatory and functional intestinal diseases. The use of preparations containing butyric acid and non-fermentable dietary fibers is a promising direction in the prevention of colon cancer. It is necessary to carry out further studies in the mentioned direction, which will allow optimizing the dose and duration of treatment with the drug Colonzak, as well as to determine the groups of patients most sensitive to treatment with multicomponent coloprotectors.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.